Clinical Trials Logo

Residual Glioma clinical trials

View clinical trials related to Residual Glioma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04164901 Active, not recruiting - Recurrent Glioma Clinical Trials

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Start date: January 5, 2020
Phase: Phase 3
Study type: Interventional

Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. Approximately 340 participants are planned to be randomized 1:1 to receive orally administered vorasidenib 40 mg QD or placebo.